Physician profile
John K Page
NPI 1871679654
$3,719.04
in general payments reported to CMS, 2019-2025
44 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $627 · 2021: $759 · 2022: $610 · 2023: $372 · 2024: $471 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $477.20 | 2019-2025 | Breztri |
| Amgen INC. | $269.81 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $244.55 | 2020-2023 | |
| Abbvie INC. | $231.82 | 2021-2025 | |
| Novo Nordisk INC | $225.66 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $220.40 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Antares Pharma, INC. | $215.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $206.62 | 2019-2021 | |
| Glaxosmithkline, LLC. | $151.19 | 2021-2024 | Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $148.57 | 2020-2022 | |
| Medtronic, INC. | $129.57 | 2021-2023 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $96.76 | 2019-2022 | |
| Pfizer INC. | $96.63 | 2023-2024 | |
| Axsome Therapeutics, INC. | $80.90 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $71.89 | 2020-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.